No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 0 fiscal years + TTM
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for LB Pharmaceuticals Inc Common Stock (LBRX) stock was $34.26 as of Oct 6, 2026, 4:00 PM EDT, down 1.04% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +129.1%
This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.
Biotechnology · New York, NY
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-1.62
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.71
vs Estimate
$-0.80
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1LBRX | $982.46M | $34.26 | -1.04% | +129.12% | N/A | N/A | N/A |
| 2MGTX | $981.66M | $10.60 | -2.93% | +29.07% | -3.10% | N/A | vs LBRX |
| 3LTGO | $978.09M | $16.26 | -2.22% | N/A | N/A | N/A | vs LBRX |
| 4PCRX | $973.93M | $24.76 | -1.16% | +0.84% | -12.27% | -3.60% | vs LBRX |
| 5VOR | $992.14M | $18.31 | -1.45% | -50.23% | -42.54% | N/A | vs LBRX |
| 6PRCT | $996.65M | $17.51 | -1.74% | -50.29% | -14.36% | N/A | vs LBRX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 9 analysts
Average Price Target
$54.78
+59.9% upside
Low
$35.00
Current
$34.26
High
$78.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-1.71 | $-1.62 | $-1.51 | 4 |
| Quarter ending Dec 2026 | $-1.82 | $-1.63 | $-1.46 | 4 |
| Quarter ending Mar 2027 | $-1.50 | $-1.50 | $-1.50 | 1 |
| Quarter ending Jun 2027 | $-1.42 | $-1.42 | $-1.42 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-5.87 | $-5.63 | $-5.33 | 6 |
| FY 2027 | $-6.07 | $-5.14 | $-3.81 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $0.00 | $0.00 | $0.00 | 0 |
| FY 2027 | $0.00 | $0.00 | $0.00 | 0 |
